A Phase 1 Randomized Blinded Placebo-Controlled Single-Ascending-Dose Study to Evaluate the Safety Tolerability and Pharmacokinetics of BIIB076 in Healthy Volunteers and Subjects with Alzheimer's Disease



Study Overview

The purpose of this study is to evaluate the safety and tolerability of BIIB076, and to measure how it moves through and is eliminated by the body.


Study Description

The purpose of this study is to evaluate the safety and tolerability of BIIB076, and to measure how it moves through and is eliminated by the body.

Additional Information:

Participants will be paid for their participation.



Research Study Identifier: TX7969
ClinicalTrials.gov Identifier: NCT1706911662
Principal Investigator: Martin Farlow


Currently Recruiting

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.